Clinical Trials Browser

Recruiting × Pathologic Complete Response × Breast × Clear all

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

Phase NA Recruiting

160 enrolled

Breast

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT07166185 2025-09-10

NEOTRAPSCAL

Recruiting

70 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

180 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05416164 2025-03-26

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

Phase NA Recruiting

595 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05976815 2025-03-26

KEYMOVE

Phase NA Recruiting

86 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Motor Activity

NCT05918328 2025-03-07

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

610 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05350722 2024-12-30

ABLATIVE-2

Phase NA Recruiting

100 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT06276868 2024-12-17

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Phase 2 Recruiting

71 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

Clinical Trials

N01-A-PICIT-GT

I-SPY

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

NEOTRAPSCAL

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

KEYMOVE

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

ABLATIVE-2

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer